Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab Extension Study in Retinal Vascular Diseases in China
CTR20211488Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of faricimab in diabetic macular edema (DME), branch retinal vein occlusion (BRVO), exudative macular degeneration, central retinal vein occlusion with macular edema, macular edema, sponsored by Roche. Started Jul 2021; status: completed.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)branch retinal vein occlusion (BRVO)exudative macular degenerationcentral retinal vein occlusion with macular edemamacular edema
Beyond the preview
Go deeper on CTR20211488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211488.